The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Bruce, S. E.
* Articles by Keller, M. B.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Bruce, S. E.
* Articles by Keller, M. B.
Related Collections
* Panic Disorder
* Phobic Disorders
* Antidepressants
* Anxiolytics
*Related Article
Am J Psychiatry 160:1432-1438, August 2003
© 2003 American Psychiatric Association


Article

Are Benzodiazepines Still the Medication of Choice for Patients With Panic Disorder With or Without Agoraphobia?

Steven E. Bruce, Ph.D., Russell G. Vasile, M.D., Robert M. Goisman, M.D., Carl Salzman, M.D., Megan Spencer, B.S., Jason T. Machan, Ph.D., and Martin B. Keller, M.D.

OBJECTIVE: Recently, pharmacological treatment guidelines for panic disorder have changed as newer treatment options have become available. The authors examined how the use of psychotropic drugs has shifted over the course of 10 years to determine if prescribing patterns have changed to reflect these revised treatment guidelines. METHOD: A total of 443 patients with panic disorder were enrolled in the Harvard/Brown Anxiety Research Project, a prospective longitudinal study of anxiety disorders. These patients were interviewed over the course of 10 years to examine their use of psychotropic medications. RESULTS: Despite efforts aimed at increasing the use of selective serotonin reuptake inhibitors (SSRIs) in patients with panic disorder (e.g., APA’s practice guideline for panic disorder, Food and Drug Administration approval of particular SSRIs for the treatment of panic disorder), only a modest increase in their use was found. Treatment patterns for psychotropic drugs appear to have remained stable over the past decade, with benzodiazepines being the most commonly used medication for panic disorder. In comparison, SSRI use throughout the follow-up period has remained low. Patients using an SSRI did not have a more favorable clinical course than those using a benzodiazepine, nor were there significantly better rates of remission in patients using SSRIs and benzodiazepines concomitantly. CONCLUSIONS: These results highlight a gap between pharmacological treatment guidelines and actual delivery of care in that recommendations to use SSRIs to treat panic disorder are not being followed. Factors potentially associated with promoting and ignoring treatment recommendations are discussed.


Related Article:

In This Issue
Am J Psychiatry 2003 160: A72. [Full Text] [PDF]



This article has been cited by other articles:


Home page
AJGPHome page
C. I. P. Benitez, K. Smith, R. G. Vasile, R. Rende, M. O. Edelen, and M. B. Keller
Use of Benzodiazepines and Selective Serotonin Reuptake Inhibitors in Middle-Aged and Older Adults With Anxiety Disorders: A Longitudinal and Prospective Study
Am J Geriatr Psychiatry, January 1, 2008; 16(1): 5 - 13.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
A. KESHEN
Benzodiazepines Versus Antidepressants for Panic Disorder
Am J Psychiatry, July 1, 2004; 161(7): 1311 - 1311.
[Full Text] [PDF]


Home page
BMJHome page
Minerva
BMJ, August 23, 2003; 327(7412): 458 - 458.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org